Keywords: phase, ii, results, r-pr, taxotere, rhone-poulenc, rorer
PHASE II RESULTS WITH R-PR'S TAXOTERE
Article | 07 June 1993
Rhone-Poulenc Rorer's taxoid compound Taxotere (docetaxel), a follow-up to the already successful Taxol (paclitaxel) from Bristol-Myers Squibb, has proved itself ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
